| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. | Clin Cancer Res | 2011 | 1.17 |
| 2 | Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. | PLoS One | 2012 | 1.02 |
| 3 | Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. | Mol Cancer Ther | 2006 | 0.91 |
| 4 | Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. | Biochem Pharmacol | 2011 | 0.87 |
| 5 | Identification of a novel inhibitor of urokinase-type plasminogen activator. | Mol Cancer Ther | 2007 | 0.84 |
| 6 | p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors. | Mol Cancer Ther | 2003 | 0.80 |